Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Neutralizing | 15 | 2024 | 285 | 1.280 |
Why?
|
| HIV Antibodies | 12 | 2023 | 243 | 1.170 |
Why?
|
| HIV-1 | 14 | 2023 | 1239 | 1.090 |
Why?
|
| Antibodies, Viral | 7 | 2024 | 266 | 0.710 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 5 | 2024 | 36 | 0.690 |
Why?
|
| Neutralization Tests | 9 | 2024 | 106 | 0.650 |
Why?
|
| AIDS Vaccines | 5 | 2022 | 150 | 0.630 |
Why?
|
| Leishmania donovani | 5 | 2002 | 5 | 0.620 |
Why?
|
| DNA, Kinetoplast | 4 | 2002 | 4 | 0.580 |
Why?
|
| HIV Envelope Protein gp120 | 7 | 2019 | 104 | 0.580 |
Why?
|
| Cross Reactions | 4 | 2024 | 44 | 0.510 |
Why?
|
| HIV Infections | 14 | 2023 | 4946 | 0.480 |
Why?
|
| Epitopes | 5 | 2022 | 97 | 0.390 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 84 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 5 | 2022 | 137 | 0.380 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 220 | 0.370 |
Why?
|
| Humans | 30 | 2024 | 14077 | 0.360 |
Why?
|
| Leishmaniasis, Visceral | 5 | 2002 | 5 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 10 | 2014 | 260 | 0.330 |
Why?
|
| HIV Envelope Protein gp160 | 2 | 2020 | 22 | 0.330 |
Why?
|
| Dog Diseases | 5 | 2014 | 5 | 0.310 |
Why?
|
| Molecular Sequence Data | 11 | 2014 | 263 | 0.310 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2005 | 3 | 0.310 |
Why?
|
| Animals | 16 | 2014 | 1063 | 0.290 |
Why?
|
| Receptors, IgG | 2 | 2024 | 28 | 0.280 |
Why?
|
| Ixodidae | 1 | 2005 | 1 | 0.250 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 2 | 0.250 |
Why?
|
| Insect Proteins | 1 | 2005 | 14 | 0.250 |
Why?
|
| HIV Seropositivity | 4 | 2023 | 263 | 0.250 |
Why?
|
| Base Sequence | 8 | 2005 | 149 | 0.240 |
Why?
|
| Immune Evasion | 2 | 2022 | 31 | 0.230 |
Why?
|
| Signal Transduction | 1 | 2024 | 33 | 0.230 |
Why?
|
| Antibody Specificity | 3 | 2020 | 30 | 0.230 |
Why?
|
| Leishmania infantum | 3 | 2014 | 3 | 0.220 |
Why?
|
| Amino Acid Sequence | 6 | 2019 | 139 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2022 | 21 | 0.200 |
Why?
|
| Polysaccharides | 3 | 2023 | 45 | 0.190 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 22 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 6 | 0.180 |
Why?
|
| Protein Binding | 5 | 2021 | 62 | 0.180 |
Why?
|
| Vagina | 2 | 2019 | 91 | 0.180 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1999 | 16 | 0.180 |
Why?
|
| DNA Probes | 1 | 2000 | 3 | 0.170 |
Why?
|
| Single-Chain Antibodies | 1 | 2020 | 5 | 0.170 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2019 | 4 | 0.170 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2022 | 28 | 0.170 |
Why?
|
| Genitalia, Female | 1 | 2019 | 17 | 0.160 |
Why?
|
| Lysine | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2018 | 8 | 0.160 |
Why?
|
| Sequence Alignment | 3 | 2005 | 59 | 0.160 |
Why?
|
| DNA, Protozoan | 7 | 2002 | 10 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 2 | 2015 | 24 | 0.150 |
Why?
|
| Virus Replication | 2 | 2015 | 87 | 0.140 |
Why?
|
| Leishmaniasis, Cutaneous | 3 | 2002 | 3 | 0.130 |
Why?
|
| Integrins | 1 | 2015 | 9 | 0.120 |
Why?
|
| Female | 11 | 2019 | 8751 | 0.120 |
Why?
|
| Genes, Immunoglobulin | 1 | 2015 | 5 | 0.120 |
Why?
|
| Germ Cells | 1 | 2015 | 8 | 0.120 |
Why?
|
| Mutation | 2 | 2023 | 299 | 0.120 |
Why?
|
| Leishmaniasis | 1 | 2014 | 1 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2014 | 5 | 0.120 |
Why?
|
| Ileum | 1 | 2014 | 3 | 0.120 |
Why?
|
| Microbiota | 1 | 2014 | 30 | 0.110 |
Why?
|
| Mannose | 1 | 2010 | 5 | 0.090 |
Why?
|
| Algal Proteins | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lectins | 1 | 2010 | 8 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2010 | 23 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 1 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 1990 | 11 | 0.090 |
Why?
|
| Leishmania | 2 | 2000 | 2 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 1990 | 12 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 380 | 0.090 |
Why?
|
| HIV | 1 | 2012 | 380 | 0.080 |
Why?
|
| Antibody Diversity | 1 | 2009 | 2 | 0.080 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 10 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2010 | 107 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 117 | 0.080 |
Why?
|
| Dogs | 5 | 2014 | 8 | 0.080 |
Why?
|
| Genetic Variation | 2 | 1999 | 169 | 0.080 |
Why?
|
| Antibodies | 2 | 2022 | 25 | 0.070 |
Why?
|
| Adult | 5 | 2019 | 5664 | 0.070 |
Why?
|
| Alleles | 2 | 2018 | 134 | 0.070 |
Why?
|
| Phylogeny | 2 | 2019 | 231 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 33 | 0.060 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2005 | 1 | 0.060 |
Why?
|
| COS Cells | 1 | 2005 | 2 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 10 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 29 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2005 | 32 | 0.060 |
Why?
|
| Models, Molecular | 2 | 2018 | 84 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 77 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2019 | 303 | 0.060 |
Why?
|
| Blotting, Southern | 2 | 2002 | 7 | 0.060 |
Why?
|
| Parasitemia | 2 | 2002 | 3 | 0.060 |
Why?
|
| Solvents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cattle Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Tick Infestations | 1 | 2002 | 1 | 0.050 |
Why?
|
| Ticks | 1 | 2002 | 1 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 39 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 1999 | 180 | 0.050 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2021 | 2 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2021 | 6 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2021 | 7 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 15 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 409 | 0.050 |
Why?
|
| Blood Donors | 1 | 2021 | 19 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 25 | 0.050 |
Why?
|
| Cell Line | 2 | 2011 | 92 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2000 | 19 | 0.040 |
Why?
|
| Receptors, Fc | 1 | 2019 | 10 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 1999 | 14 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2019 | 11 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2019 | 11 | 0.040 |
Why?
|
| Leishmania tropica | 1 | 1999 | 1 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 10 | 0.040 |
Why?
|
| Reproductive Tract Infections | 1 | 2019 | 8 | 0.040 |
Why?
|
| Trypanosomatina | 1 | 1999 | 1 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2019 | 47 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1999 | 40 | 0.040 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 49 | 0.040 |
Why?
|
| Viremia | 1 | 2019 | 66 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2018 | 17 | 0.040 |
Why?
|
| Peptides | 1 | 2018 | 40 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 430 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 150 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 194 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 2357 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 1131 | 0.030 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2015 | 6 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 5 | 0.030 |
Why?
|
| Viral Load | 1 | 2019 | 808 | 0.030 |
Why?
|
| Tunisia | 1 | 2014 | 3 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2014 | 4 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2014 | 32 | 0.030 |
Why?
|
| South Africa | 2 | 2019 | 7312 | 0.030 |
Why?
|
| Middle Aged | 2 | 2019 | 3425 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 14 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 60 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2012 | 64 | 0.030 |
Why?
|
| Adolescent | 1 | 2019 | 2858 | 0.020 |
Why?
|
| Antibodies, Protozoan | 2 | 2002 | 3 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 15 | 0.020 |
Why?
|
| Plant Lectins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Glycosylation | 1 | 2010 | 17 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 19 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 43 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 39 | 0.020 |
Why?
|
| Karyotyping | 1 | 1990 | 4 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1990 | 20 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2010 | 34 | 0.020 |
Why?
|
| DNA Primers | 2 | 1999 | 55 | 0.020 |
Why?
|
| Mice | 1 | 1990 | 134 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 26 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 184 | 0.020 |
Why?
|
| Male | 4 | 2002 | 6489 | 0.020 |
Why?
|
| Oman | 2 | 1999 | 2 | 0.020 |
Why?
|
| Prevalence | 2 | 2002 | 1149 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2001 | 1377 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2002 | 2 | 0.010 |
Why?
|
| RNA, Protozoan | 1 | 2002 | 5 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 11 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 14 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 17 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 27 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 35 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 30 | 0.010 |
Why?
|
| Malta | 1 | 2002 | 1 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 72 | 0.010 |
Why?
|
| Spleen | 1 | 2002 | 9 | 0.010 |
Why?
|
| Fibrosis | 1 | 2002 | 11 | 0.010 |
Why?
|
| Ovary | 1 | 2002 | 5 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 13 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 168 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 74 | 0.010 |
Why?
|
| Antigens, Protozoan | 1 | 2001 | 1 | 0.010 |
Why?
|
| Brazil | 1 | 2001 | 43 | 0.010 |
Why?
|
| Peru | 1 | 2000 | 8 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 5 | 0.010 |
Why?
|
| Skin Tests | 1 | 1999 | 14 | 0.010 |
Why?
|
| Sudan | 1 | 1999 | 9 | 0.010 |
Why?
|
| Pakistan | 1 | 1999 | 2 | 0.010 |
Why?
|
| RNA Editing | 1 | 1999 | 3 | 0.010 |
Why?
|
| RNA, Guide | 1 | 1999 | 3 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 168 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1999 | 367 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2001 | 939 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1999 | 767 | 0.010 |
Why?
|